CALGB 9511 used pegaspargase (PEG-ASP) in lieu of the native enzyme. The aim was to compare differences in overall survival (OS) and disease-free survival (DFS) between patients who did and did not achieve asparagine depletion, defined by enzyme levels >0.03 units/ml plasma for 14 consecutive days after at least one of four planned PEG-ASP administrations.
Introduction
Asparaginase (ASP) hydrolyzes asparagine to aspartate and ammonia. Acute lymphoblastic leukemia (ALL) cells lack asparagine synthetase and are dependent on an exogenous source of asparagine for survival. Rapid depletion of asparagine results in the selective killing of ALL cells, whereas normal cells are able to synthesize asparagine. 1 Three preparations of ASP are available: one from Escherichia coli (E. coli), one from Erwinia carotovora and pegaspargase (PEG-ASP), the monoethoxypolyethylene glycol succinimidyl conjugate of E. coli L-asparaginase. PEG-ASP has decreased immunogenicity and a longer halflife than the other two enzymes 2, 3 and maintains asparagine depletion equivalent to higher doses and prolonged administration of the native preparations. 4 The effect of PEG-ASP was previously studied in three relapsed [5] [6] [7] ALL trials and in two pediatric induction 8, 9 and one adult 10 induction ALL studies. All have shown it to be welltolerated with comparable or better asparagine depletion. A randomized trial 9 in childhood ALL demonstrated a correlation between ASP activity and asparagine depletion. None of these trials demonstrated an effect of asparagine depletion on outcome.
The Cancer and Leukemia Group B (CALGB) used PEG-ASP in lieu of the native enzyme during induction and early intensification therapy of adult ALL patients. The aim of the study was to explore differences in overall survival (OS) and disease-free survival (DFS) of those patients who achieved asparagine depletion compared to those who did not.
Methods

Patients.
Patients were eligible if they had untreated ALL or acute undifferentiated leukemia.
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Burkitt-type ALL was excluded. Central immunophenotyping, pathology and karyotype reviews anti-ASP antibody titers were measured centrally using previously established methods. 3, 14, 15 Asparagine depletion was defined as ASP levels >0.03 units/ml for 14 consecutive days after at least one of four possible administrations of PEG-ASP.
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Response criteria. Hematologic CR was defined by previously established criteria. 12 OS was defined as the interval between study entry and death. DFS was defined as the interval between date of CR and relapse or death, whichever occurred first. Patients were censored at the date last seen alive (for OS) and the date last seen without progression (for DFS). No censoring was performed for allogeneic transplantation. Relapse after CR was defined by the appearance of The hazard ratio (HR) of age was given in terms of 10-year increments. Covariates in these models were selected based upon their clinical significance in prior CALGB trials. 12 All were kept in the model regardless of their p-value. 19 HR with 95% confidence intervals (CI) were used to describe the association of the predictor variables with DFS and OS.
Immunophenotype data (B-versus T-lineage) 20 were available on only 62 of the 85 patients with pharmacokinetic data, and therefore immunophenotype was not included in the regression models. Instead, univariate statistics were used to describe its association with asparagine depletion, OS, and DFS. 
Results and Discussion
Characteristics of patients with and without asparagine depletion are described in Table   1A . Anti-ASP antibodies were detected in six of 63 (9.5%) patients who achieved asparagine depletion at some point as compared to seven of 22 (31.8%) patients who did not (P=0.012).
Although anti-ASP antibodies were significantly more prevalent in patients who did not achieve asparagine depletion, when using a variety of models to evaluate the predictive ability of antibody level for various outcomes, none was suggestive of meaningful associations. These data suggest that, in this small cohort, even those patients who eventually developed antibodies to ASP, thus presumably neutralizing any further biological activity, did not experience less overall anti-leukemia effect.
All 85 patients with pharmacokinetic and antibody analyses were used to examine the association of asparagine depletion with OS. Seventy-one patients with pharmacokinetic and antibody analyses who achieved CR were used to examine the association of asparagine depletion with DFS. Univariate analyses suggested that the patients who did not achieve asparagine depletion even once had inferior OS and DFS (Table 1B; Figure 1 ). Increasing age was associated with decreasing total number of PEG-ASP doses (Table 1A) Immunophenotype data were available on 62 of the 85 patients for whom pharmacokinetic and antibody analyses were available (Table 1A) . Patients with B-lineage ALL had an inferior DFS and OS as compared to patients with T-lineage ALL (Table 1C) . The relationship between immunophenotype and asparagine depletion has not been previously reported and appears provocative. A larger study is needed to address the joint association of asparagine depletion and immunophenotype on outcome. This is the first demonstration that effective asparagine depletion with PEG-ASP as part of an intensive multi-agent therapeutic regimen in ALL is feasible in adults and is associated with improved outcomes. This observation requires validation in larger patient cohorts. 
